A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Abemaciclib (Primary) ; Belzutifan (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 09 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.